Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer [PDF]
HeliyonBackground: Rearranged during transfection (RET) gene fusion is a target for non-small cell lung cancer (NSCLC) treatment, and RET inhibitors are approved for advanced NSCLC.
Jia Zhong, Jie Wang, Jianchun Duan
exaly +4 more sources
RET signaling pathway and RET inhibitors in human cancer [PDF]
Frontiers in Oncology, 2022 Rearranged during transfection (RET) receptor tyrosine kinase was first identified over thirty years ago as a novel transforming gene. Since its discovery and subsequent pathway characterization, RET alterations have been identified in numerous cancer ...
Angelina T. Regua +3 more
doaj +2 more sources
Assessing the Effectiveness of Selective RET Inhibitors in RET-Positive Cancers through Fluorodeoxyglucose Uptake Analysis [PDF]
DiagnosticsSelective RET inhibitors, such as selpercatinib and pralsetinib, have revolutionized the treatment of cancers with RET gene alterations. These inhibitors have shown remarkable clinical efficacy, particularly in RET-driven lung cancer, medullary thyroid ...
Kalevi Kairemo +3 more
doaj +2 more sources
Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: update [PDF]
Oncology Reviews, 2018 Precision oncology is now the evidence-based standard of care for the management of many advanced non-small cell lung cancers (NSCLC). Notably, new molecular profiling technologies have permitted dynamic growth in the identification of actionable driver ...
Luis Mendoza
doaj +2 more sources
Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer [PDF]
Frontiers in OncologyThe global incidence of thyroid cancer has increased significantly, and patients with advanced, recurrent, or radioiodine-refractory disease face a severe shortage of effective treatment options.
Yulu Zhou +9 more
doaj +2 more sources
Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers [PDF]
Cell Reports Medicine, 2023 Mark E Zafereo, Vivek Subbiah
exaly +2 more sources
Precision therapy for RET-altered cancers with RET inhibitors [PDF]
Trends in Cancer, 2021 Blaine Mooers, Jie Wu, Vivek Subbiah
exaly +2 more sources
The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis [PDF]
Investigational New Drugs, 2023 Ke JY, Huang S, Jing ZT, Duan MC.
exaly +2 more sources
Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: “Shadows and Fogs” [PDF]
CancersFilippo de Marinis +2 more
exaly +2 more sources
Precision oncology for RET-related tumors
Frontiers in Oncology, 2022 Aberrant activation of the RET proto-oncogene is implicated in a plethora of cancers. RET gain-of-function point mutations are driver events in multiple endocrine neoplasia 2 (MEN2) syndrome and in sporadic medullary thyroid cancer, while RET ...
Antonella Verrienti +7 more
doaj +1 more source